JHOP - February 2021 Vol 11, No 1

Optimizing Response to Enasidenib with Dose Escalation in Relapsed or Refractory Acute Myeloid Leukemia

Amany R. Keruakous, MD; Sarah A. Schmidt, PharmD; Marcus T. Autry, PharmD; Julia Ye, PharmD Candidate; Phoi Nguyen, PharmD Candidate; Silas Day

Original Article

Optimizing Daratumumab Infusion: Assessing the Safety and Feasibility of Omitting Preinfusion Medications and Decreasing Infusion Time

Justine Preedit, PharmD; Anya Yudchyts, PharmD, BCOP

Olanzapine versus Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Patients Receiving Single-Day High-Dose Melphalan

Ekim Ekinci, PharmD, MS, BCOP; James E. Cox, PharmD, BCOP; Joe E. Ensor, PhD; Edward T. McLean, PharmD, BCOP; Carlos A. Ramos, MD; Premal D. Lulla, MD; Rammurti T. Kamble, MD; George Carrum, MD

Evaluation of Infusion-Related and Hypersensitivity Reactions to Chemotherapy Over a Decade at a Community Cancer Center

Sarah Maryon Hayes, PharmD, BCOP; Jeremy Whalen, PharmD, BCOP; Nick Schutz, PharmD; Joseph Levine, MD

Electrolyte Abnormalities and the Associated Risk for Atrial Fibrillation After Autologous Hematopoietic Stem-Cell Transplant

Natalie Schulze, PharmD; Kyle LaPorte, PharmD; Carol Breikreutz, PharmD, BCOP; Tobias Meissner, PhD; R. Vinod Parameswaran, MD, FRCPath, MRCP; Renju Raj, MD; Kelly McCaul, MD, ABIM, FRCPC

FDA Oncology Update

FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations

Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma

Tagrisso Receives New Indication as Adjuvant Therapy for NSCLC with EGFR Mutations

Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients

FDA Approves Margenza for the Treatment of Metastatic HER2-Positive Breast Cancer